A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, \>=18 years of age;
kidney transplant \>=6 months and \<5 years prior to randomization;
anemia;
no ESA therapy during 3 months prior to randomization.
You may not be if
requirement for hemodialysis or peritoneal dialysis within 3 months prior to randomization;
change in Hb concentration \>=1.5g/dL during screening period;
transfusion of red blood cells during 3 months prior to randomization;
poorly controlled hypertension;
significant acute or chronic bleeding within 3 months prior to randomization.
Clareo Health | A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
